Long-term evidence depends on the medicine, the condition and the patient. SELECT followed adults with cardiovascular disease and without diabetes. Its follow-up analysis found lower rates of serious adverse events in the semaglutide group across the starting BMI categories studied [1]. In the primary trial, 33.4% of participants on semaglutide and 36.4% on placebo reported serious adverse events [7]. A separate FDA analysis detected a possible increase in a rare eye condition across GLP-1 trials [6].
Four years of semaglutide: SELECT
SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, none with diabetes. A major cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.80, 95% CI 0.72 to 0.90) [7]. A prespecified analysis then looked at weight and safety by starting BMI.
At 208 weeks, weight was down 10.2% on semaglutide against 1.5% on placebo. Serious adverse events ran lower on semaglutide in every BMI group. Per 100 years of observation, the rates were 43.23, 43.54, 51.07 and 47.06 on semaglutide. On placebo they were 50.48, 49.66, 52.73 and 60.85 [1].
Adverse events led to permanent discontinuation in 16.6% of the semaglutide group and 8.2% of the placebo group. In the semaglutide group, that rate rose as starting BMI fell[1].
Two years: STEP 5
STEP 5 randomized 304 adults to semaglutide 2.4 mg or placebo for 104 weeks [2]. Mean weight fell by 15.2% on semaglutide and 2.6% on placebo. The trial completion rate was 92.8%.
Gastrointestinal adverse events were reported by 82.2% on semaglutide and 53.9% on placebo. Most were mild to moderate [2]. The side-effect guide explains how common symptoms vary during dose escalation.
A meta-analysis pooled four trials of at least 68 weeks, with 3,087 participants [3]. The risk of gastrointestinal events was higher on semaglutide, a relative risk of 1.47 (95% CI 1.28 to 1.68). The authors add that most were transient, mild to moderate, and did not require stopping treatment.
Three and a half years of tirzepatide: SURMOUNT-1
SURMOUNT-1 followed 1,032 adults with obesity and prediabetes on tirzepatide 5, 10 or 15 mg or placebo for 176 weeks, then 17 weeks off [4]. Weight was down 12.3%, 18.7% and 19.7% by dose, against 1.3% on placebo [4].
On safety, the most common adverse events other than COVID-19 were gastrointestinal. Most were mild to moderate, and they occurred mainly during dose escalation in the first 20 weeks. The authors reported no new safety signals over the three years [4].
The warning that no trial has settled
The Wegovy label for semaglutide carries a boxed warning on thyroid C-cell tumors [5]. In rodents, semaglutide causes them, dependent on dose and treatment duration. Whether it does so in humans is unknown, because the label states that human relevance has not been determined.
The label’s rule is a condition, not a probability. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, or with MEN 2. Four years of trial follow-up does not resolve a question framed in those terms.
FDA’s November 2026 warning about a rare eye condition
On November 9, FDA required a warning about a possible increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) for GLP-1 medicines. NAION can cause sudden, painless loss of vision, usually in one eye. FDA found 10 probable cases in GLP-1 groups and five in comparator groups across 126 trials. That was 6.4 versus 3.8 cases per 100,000 person-years [6].
The pooled figures span several medicines and do not measure a particular person’s risk. FDA advises people to report sudden vision loss or other new vision changes in one eye immediately [6].
What the trials do not answer
These trials give limited information beyond their follow-up periods or for people who would not have qualified. Trials that tracked weight regain after stopping treatment measured what happened after withdrawal. The maintenance-dose guide covers a trial that compared two continued tirzepatide doses with switching to placebo.
A review of real-world studies in people with obesity and without diabetes found that about a third were still taking them at one year [8].
What long term costs
A benefit that depends on continued treatment is a recurring bill. Tirzepatide’s median published figure across the sellers tracked here is $269 a month. The range runs 6.4 times, from $86 to $549.99, across 159 sellers. Set that beside what the whole market charges before a first order.
Dose matters to both halves. The 10 and 15 mg doses produced more weight loss than 5 mg, and sellers often publish nothing about what a higher dose costs. Over years, the gap between an advertised price and the billed one compounds. Price figures are computed from this site’s own records at build time, most recently read November 2026, across 183 priced sellers.